• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Cerus Corporation

    5/30/25 4:01:40 PM ET
    $CERS
    EDP Services
    Technology
    Get the next $CERS alert in real time by email
    SD 1 cers_-_form_sd_2025.htm SD SD

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM SD

    Specialized Disclosure Report

    Cerus Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    000-21937

    (State or other jurisdiction of incorporation)

    (Commission file number)

     

     

     

    1220 Concord Ave, Suite 600

    Concord, California

    94520

    (Address of principal executive offices)

    (Zip Code)

    Chrystal N. Jensen

    Chief Legal Officer and General Counsel

    (925) 288-6000

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:

    

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

    □

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _______________.


    Section 1—Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    Conflict Minerals Disclosure

    This Form SD of Cerus Corporation (the “Company”) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934 (the “Rule”) for the reporting period January 1, 2024 to December 31, 2024 (the “Reporting Period”). The Rule requires disclosure of certain information when a company manufactures or contracts to manufacture products and the minerals specified in the Rule are necessary to the functionality or production of those products. The specified minerals, which are collectively referred to in this disclosure as the “Conflict Minerals,” are gold, columbite-tantalite (coltan), cassiterite and wolframite, including their derivatives, which are limited to tantalum, tin and tungsten. The “Covered Countries,” for the purposes of the Rule and this disclosure, are the Democratic Republic of the Congo, the Republic of the Congo, the Central African Republic, South Sudan, Uganda, Rwanda, Burundi, Tanzania, Zambia and Angola. As described in this disclosure, the Company contracts to manufacture one product which contains Conflict Minerals that are necessary to the functionality or production of such product (the “Necessary Conflict Minerals”). As discussed below, following the performance of a reasonable country-of-origin inquiry (“RCOI”) and due diligence on the source and chain of custody of the Necessary Conflict Minerals, the Company has reasonably concluded that is unable to definitively determine whether Necessary Conflict Minerals used in the manufacture of its Covered Product originated from a Covered Country.

    This disclosure relates to one product, which is referred to in this disclosure as a “Covered Product”: (i) for which Conflict Minerals are necessary to its functionality or production; (ii) that were manufactured, or contracted to be manufactured, by the Company; and (iii) for which the manufacture was completed during calendar year 2024. For the Reporting Period, the INT-200 INTERCEPT Illuminator (the “Illuminator”) is the Covered Product.

    Reasonable Country–of-Origin Inquiry

    The Company has conducted a good faith reasonable country-of-origin inquiry regarding the Necessary Conflict Minerals. This good faith RCOI was reasonably designed to determine whether any of the Necessary Conflict Minerals originated in the Covered Countries and whether any of the Necessary Conflict Minerals may be from recycled or scrap sources. The Company’s RCOI comprises the conduct described under the caption “Description of Due Diligence Measures” below.

    The Illuminator is manufactured by the Company’s contract manufacturer (the “Manufacturer”) according to the Company-provided specifications and contains over 850 components purchased by the Manufacturer from over 110 distributors or suppliers. Due to the Illuminator’s level of regulatory classification in most jurisdictions where the Company plans to sell the Illuminator, changes to its design or components will require significant regulatory review and approval. The Company received its first regulatory approval under the CE Certificate of Conformity in March 2025 for commercial sale and distribution of the Illuminator. The supply chain for components of the Illuminator is complex and includes primarily third-party suppliers or distributors between the Manufacturer of the Illuminator and the original sources of the Necessary Conflict Minerals contained therein. The Company does not purchase any Necessary Conflict Minerals directly from mines, smelters or refiners and does not make any purchases in any of the Covered Countries. Therefore, the Company must rely on the Manufacturer and its upstream component suppliers to provide information on the origin of the Conflict Minerals, if any, contained in the components and materials used in the manufacture of the Illuminator and to identify the applicable smelters and refiners of Necessary Conflict Minerals in the Company’s supply chain. The information provided by the Manufacturer and its upstream component suppliers may be inaccurate or incomplete or subject to other irregularities. In addition, because of the Company’s relative location within the supply chain in relation to the actual extraction and transport of Conflict Minerals, the Company’s ability to verify the accuracy of information reported by the Manufacturer and its upstream component suppliers is limited. Accordingly, the Company cannot provide absolute assurance regarding the source and chain of custody of the Necessary Conflict Minerals in the Illuminator.

    The Company’s agreement with the Manufacturer of the Illuminator, among other things, requires the Manufacturer to provide to the Company a full report each year identifying the sources of any Necessary Conflict Minerals, if any, contained in the Illuminator. For the reporting period, January 1, 2024 to December 31, 2024, the Manufacturer provided its required report identifying the suppliers or distributors of components in the Illuminator manufactured during the Reporting Period that contained Necessary Conflict Minerals. Of the 854 components analyzed, approximately 31%, or 266 components, do not contain any Conflict Minerals. The remaining 69%, or 588 components, were further analyzed with respect to possible Conflict Minerals contained therein. Approximately 5%, or 45 components, did not originate from a Covered Country or did not originate from a smelter or refiner known to finance or benefit armed groups in the Covered Countries. Nearly 49%, or 414 components, were determined to be from a Covered Country but not from a smelter or refiner known to finance or benefit armed groups in the Covered Countries. Approximately 15%, or 129 components, were of an unknown origin or it was undeterminable if they originated from a smelter or refiner known to finance or benefit armed groups in the Covered Countries.

    Design of Due Diligence

    The Company’s due diligence measures have been designed to conform, in all material respects, to the framework in the Organisation for Economic Co-operation and Development Due Diligence Guidance for Responsible Supply Chain of Minerals from


    Conflict-Affected and High Risk Areas: Third Edition, including the related supplements on gold, tin, tantalum and tungsten (the “OECD Guidance”), consistent with the Company’s position as a downstream company in the Conflict Minerals supply chain.

    Description of Due Diligence Measures

    The Company’s due diligence measures performed with respect to Covered Product manufactured during 2024 included the following:

    Establish Strong Company Management Systems

    •
    Conflict Minerals Team. The Company’s Conflict Minerals management team for 2024 consisted of members of its manufacturing and legal departments, including its VP, Device Development, Hardware and Software and its Associate General Counsel to oversee the due diligence efforts and consider and address potential risks within the Company’s supply chain.
    •
    System of Controls and Transparency. The management team collectively devised a Conflict Minerals plan for management and supplier engagement. The system is designed to collect and retain the information necessary to support the Company’s conflict minerals inquiry and reporting.
    •
    Continued Engagement with Suppliers. The Company continues to engage its direct supplier in order to obtain the required upstream supplier information for components of the Covered Product.
    •
    Grievance Mechanism. The Company has an established Whistleblower Hotline. Customers, employees or other interested parties are able to use the Hotline to provide anonymous information about the Company, including grievances or other information related to Conflict Minerals.

    Identify and Assess Risk in the Supply Chain

    •
    Partnered with the Company’s Manufacturer to obtain and analyze the data reported by upstream component suppliers to determine whether any suppliers provided Conflict Minerals for use in the manufacture of the Illuminator that were sourced from Covered Countries; and
    •
    Reviewed the reports completed by the Company’s Manufacturer for the Illuminator.

    Design and Implement a Strategy to Respond to Identified Risks

    As noted above under “Establish Strong Company Management Systems,” the Company has established a reporting protocol under which the Conflict Minerals management team reports risks arising from its diligence exercise to executives of the Company. The protocol is designed to enable the Conflicts Minerals management team to report, among other things, identified risks in the supply chain. The Company’s risk management strategy includes maintaining close contact with the Manufacturer in order to (a) obtain the required upstream supplier information for components of the Covered Product, (b) pursue the Company’s goal of having a conflict-free supply chain, and (c) attempt to influence the selection, to the extent practicable, of alternative upstream suppliers that can provide assurance that their components do not contain Conflict Minerals from Covered Countries that directly or indirectly finance armed groups in the Covered Countries.

    Carry Out Independent Third-Party Audit of Supply Chain

    The Company does not have any direct relationships with smelters or refiners that process Conflict Minerals, and it does not perform or direct audits of these entities within its supply chain. As an alternative, the Company has relied on information collected and provided by its Manufacturer.

    Annual Disclosure on Conflict Minerals

    The Company expects to make its disclosures hereunder publicly available on an annual basis, as required by the Rule. A copy of the Company’s Conflict Minerals Disclosure will be publicly available on the Company’s website at http://www.cerus.com/Investors/Corporate-Governance/default.aspx.

    Conclusions

    Due to the large number of suppliers upstream of the Manufacturer for the Illuminator, as well as the relatively small percentage of the Manufacturer's business that the manufacture of the Illuminator comprises, the Company was unable to obtain complete information regarding every source and chain of custody for each of the components contained in the Illuminator. To the extent that smelter or refiner information was provided through the EICC templates at the “company-level” for components used in the manufacture of the Illuminator, the Company relied on such information. In the event such information was incomplete or unavailable, the Company


    determined that it did not have sufficient information to reasonably or reliably identify the particular smelters or refiners that processed the Conflict Minerals, if any, contained in such components of the Illuminator or the country of origin of such Conflict Minerals, if any. Due to the downstream position of the Company and the Manufacturer in the supply chain of these components, it has been difficult for the Manufacturer to obtain additional information from its upstream suppliers of components for the Illuminator.

    Future Due Diligence and Risk Mitigation.

    The Company expects to continue to work closely with the Manufacturer to influence the selection, to the extent practicable, of alternative upstream suppliers that can provide assurance that their components do not contain any Conflict Minerals from Covered Countries that directly or indirectly finance armed groups in the Covered Countries.

    Cautionary Note on Forward-Looking Statements

    Forward-looking statements in this Form SD are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. Investors are cautioned that statements in this Form SD that are not strictly historical statements, including without limitation, the Company’s ability to ensure that components of the Illuminator that contain Conflict Minerals originate from non-Covered Countries, the Company’s intentions and expectations regarding future reporting, due diligence and risk mitigation efforts and strategy, constitute forward-looking statements that involve risks and uncertainties. Words such as “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “evaluates,” variations of these words, and similar expressions are intended to identify such forward-looking statements. Actual results could differ materially from the forward-looking statements. Risks and uncertainties that could cause actual results to differ include, without limitation, risks and uncertainties associated with the progress of industry and other supply chain transparency and smelter or refiner validation programs for Conflict Minerals (including the possibility of inaccurate information, fraud and other irregularities), including year-over-year changes experienced by upstream suppliers of the Illuminator components, inadequate supplier education and knowledge, limitations on the ability or willingness of suppliers to provide more accurate, complete and detailed information and limitations on the Company’s ability to verify the accuracy or completeness of any supply chain information provided by suppliers or others, as well as potential statutory or regulatory changes.

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

     

    Cerus Corporation

    By: /s/ Chrystal N. Jensen

    Chrystal N. Jensen

    Chief Legal Officer and General Counsel

    May 30, 2025

     

     

     

     


    Get the next $CERS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERS

    DatePrice TargetRatingAnalyst
    4/12/2024$5.00Buy
    Craig Hallum
    1/20/2023Buy → Neutral
    BTIG Research
    1/17/2023$3.75Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $CERS
    Financials

    Live finance-specific insights

    See more
    • Cerus Corporation Announces First Quarter 2025 Financial Results

      First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million First Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update. "We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus' mission to transform the safety and availability of transfused blood components," said William "Obi" Greenman, Cerus' president an

      5/1/25 4:00:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025

      Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay wi

      4/17/25 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results

      Full-Year and Fourth Quarter 2024 Product Revenues Increased 15% and 9%, respectively, from Prior Year Periods Fourth straight quarter of positive operating cash flows Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 – $200 million Cerus Corporation (NASDAQ:CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024. Recent highlights include: Total revenue for full-year 2024 and fourth quarter 2024 was comprised of (in thousands, except %): Three Months Ended           Twelve Months Ended         December 31,   Change   December 31,   Change   Unaudited  

      2/20/25 4:00:00 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan

      Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells Cerus Corporation (NASDAQ:CERS) today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35th Regional International Society of Blood Transfusion (ISBT) Congress being held May 31 to June 4, 2025, in Milan. "The breadth of data being presented this year underscores the broad applicability of the INTERCEPT system for platelets, plasma, and cryoprecipitated fibrinogen complex as well as the potential benefit for red blood cells," said Richard J. Benjamin, Cerus' chief medical officer. "Importantly, w

      5/29/25 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device

      France and Switzerland approve INT200 for use with the INTERCEPT Blood System for Platelets and Plasma Cerus Corporation (NASDAQ:CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product Safety (ANSM) and the other by the Swiss Agency for Therapeutic Products (Swissmedic). The INT200, the Company's next generation LED-based illumination device, was developed as the new foundational platform for the INTERCEPT Blood System, with input and feedback from global customers to enhance daily blood center operations. The contemporary vertical configuration is designed to improve workflow and ergonomics while freeing u

      5/28/25 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces First Quarter 2025 Financial Results

      First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million First Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update. "We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus' mission to transform the safety and availability of transfused blood components," said William "Obi" Greenman, Cerus' president an

      5/1/25 4:00:00 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Leadership Updates

    Live Leadership Updates

    See more
    • Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

      Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h

      7/2/24 4:00:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

      Cerus Corporation (NASDAQ:CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. "We are excited to welcome Alicia to the Cerus team," said William "Obi" Greenman, Cerus' president and chief executive officer. "As we advance on key global commercial and pipeline initiatives, our talent, leadership and organization structure across all levels of the organization w

      9/27/23 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors

      Cerus Corporation (NASDAQ:CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. "We are pleased to welcome Dr. Shan to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Dr. Shan is an accomplished, leading voice in the transfusion community, with more than twenty-five years of experience in the field, bringing a wealth of knowledge and insight to our Board. In addition, Dr. Shan has extensive experience with international blood bank practices including the Chinese transfusion market. We expect to benefit from Dr. Shan's expertise as we co

      7/5/22 5:00:00 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CERS
    SEC Filings

    See more
    • Chief Legal Officer Jensen Chrystal sold $71,085 worth of shares (49,024 units at $1.45), decreasing direct ownership by 6% to 783,294 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      3/17/25 5:02:37 PM ET
      $CERS
      EDP Services
      Technology
    • Chief Operating Officer Jayaraman Vivek K sold $110,184 worth of shares (75,989 units at $1.45), decreasing direct ownership by 5% to 1,431,326 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      3/17/25 5:01:47 PM ET
      $CERS
      EDP Services
      Technology
    • President and CEO Greenman William Mariner sold $281,174 worth of shares (193,913 units at $1.45), decreasing direct ownership by 4% to 4,115,845 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      3/17/25 5:00:46 PM ET
      $CERS
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Cerus Corporation

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      11/12/24 9:53:11 AM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      2/14/24 4:21:51 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      2/13/24 5:01:03 PM ET
      $CERS
      EDP Services
      Technology
    • Craig Hallum initiated coverage on Cerus with a new price target

      Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00

      4/12/24 8:00:30 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus downgraded by BTIG Research

      BTIG Research downgraded Cerus from Buy to Neutral

      1/20/23 10:02:56 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus downgraded by Stephens with a new price target

      Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75

      1/17/23 7:57:35 AM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SD filed by Cerus Corporation

      SD - CERUS CORP (0001020214) (Filer)

      5/30/25 4:01:40 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form DEFA14A filed by Cerus Corporation

      DEFA14A - CERUS CORP (0001020214) (Filer)

      5/23/25 12:01:02 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form 10-Q filed by Cerus Corporation

      10-Q - CERUS CORP (0001020214) (Filer)

      5/1/25 5:06:25 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gregory Dean A. bought $2,932 worth of shares (1,725 units at $1.70), increasing direct ownership by 3% to 61,725 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      1/2/25 5:46:11 PM ET
      $CERS
      EDP Services
      Technology
    • Shan Hua bought $4,975 worth of shares (2,500 units at $1.99), increasing direct ownership by 8% to 32,386 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      5/14/24 6:30:46 PM ET
      $CERS
      EDP Services
      Technology
    • Nachtsheim Jami K bought $3,578 worth of shares (2,000 units at $1.79), increasing direct ownership by 2% to 108,362 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      5/13/24 5:09:19 PM ET
      $CERS
      EDP Services
      Technology